Iptacopan sustains hemolysis control in PNH out to six years
Start here
Two long-term follow-up studies presented at EHA 2026 show that iptacopan durably controls hemolysis in paroxysmal nocturnal hemoglobinuria (PNH), with stable hematologic responses maintained over follow-up of up to four and six years. In the six-year follow-up of the phase 2 and extension studies, median treatment duration was 66.1 months. At year 6, 85.7% of patients had hemoglobin at or above 12 g/dL, LDH below 1.5 times the upper limit of normal, and normalized absolute reticulocyte counts, while 88.5% were free of transfusion dependence. FACIT-F fatigue scores improved significantly from month 6 and remained stable thereafter. The data support iptacopan's durability in PNH; further detail beyond these follow-up results has not been reported.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickEHA 2026: iptacopan long-term follow-up in PNH shows sustained hemolysis control
Two long-term follow-up studies presented at EHA 2026 show that iptacopan durably controls hemolysis in PNH, maintaining stable hematologic responses over follow-up of up to 4 and 6 years. In the 6-year follow-up of the phase 2 and extension studies, median treatment duration was 66.1 months; at year 6, 85.7% of patients had Hb at or above 12 g/dL, LDH below 1.5 x ULN and normalized ARC, 88.5% were free of transfusion dependence, and FACIT-F scores improved significantly from month 6 and remained stable.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 18:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.